Intelligent Bio Solutions begins interference study for FDA 510(k) clearance of fingerprint drug test for codeine

INTELLIGENT BIO SOLUTIONS INC.

Interference Study with 75 healthy adults to validate the system's codeine specificity against everyday substances.
Expected completion by mid-July 2026; results will be part of the FDA 510(k) submission package.
Study runs concurrently with Method Comparison Study; follows January 2026 Cut-off Study.
Partners again with CenExel Clinical Research to conduct the clinical trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.